Skip to main content
SpringerLink
Log in
Book cover

Mitochondrial Dynamics in Cardiovascular Medicine pp 621–646Cite as

Mitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 982))

Abstract

The heart continuously supplies blood to the entire body throughout the lifetime, requiring a huge amount of the bioenergy molecule adenosine triphosphate (ATP). As the major subcellular organs that produce ATP through oxidative phosphorylation and the citrate-synthesis cycle, mitochondria inevitably produce chemically reactive species as byproducts. Those species are known to be major effectors of mitochondrial dysfunction, many of which are involved in various cardiovascular diseases, causing apoptotic/necrotic loss of cardiac myocytes and/or defects in the energy balance within the myocardium. In this context, researchers have aimed to develop effective antioxidant therapies to treat cardiovascular disorders. This chapter presents an overview of the clinical trials related to antioxidant therapy and discusses the current clinical status of mitochondria-targeted antioxidants and potential future candidate molecules.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kim HK, Nilius B, Kim N, Ko KS, Rhee BD, Han J. Cardiac response to oxidative stress induced by mitochondrial dysfunction. Rev Physiol Biochem Pharmacol. 2016;170:101–27.

    Article  CAS  PubMed  Google Scholar 

  2. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol. 2015;24:325–40.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ando K, Fujita T. Metabolic syndrome and oxidative stress. Free Radic Biol Med. 2009;47:213–8.

    Article  CAS  PubMed  Google Scholar 

  5. Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H, Me LL. Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12:376–90.

    Article  CAS  PubMed  Google Scholar 

  6. Xie W, Santulli G, Reiken SR, Yuan Q, Osborne BW, Chen BX, Marks AR. Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep. 2015;5:11427.

    Google Scholar 

  7. Santulli G, Xie W, Reiken SR, Marks AR. Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci U S A. 2015;112:11389–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Page E, McCallister LP. Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol. 1973;31:172–81.

    Article  CAS  PubMed  Google Scholar 

  9. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res. 2014;114:524–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18:3871–88.

    Article  CAS  PubMed  Google Scholar 

  11. Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci. 2011;342:135–42.

    Article  PubMed  Google Scholar 

  12. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004;13:93–9.

    Article  CAS  PubMed  Google Scholar 

  13. Hinerfeld D, Traini MD, Weinberger RP, Cochran B, Doctrow SR, Harry J, Melov S. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem. 2004;88:657–67.

    Article  CAS  PubMed  Google Scholar 

  14. Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta. 1822;2012:631–8.

    Google Scholar 

  15. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69:836–41.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Greenberg ER, Baron JA, Tosteson TD, Freeman Jr DH, Beck GJ, Bond JH, Colacchio TA, Coller JA, Frankl HD, Haile RW, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med. 1994;331:141–7.

    Article  CAS  PubMed  Google Scholar 

  17. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL. Antioxidant vitamin supplements and cardiovascular disease. Circulation. 2004;110:637–41.

    Article  CAS  PubMed  Google Scholar 

  18. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol. 2008;101:14D–9D.

    Article  CAS  PubMed  Google Scholar 

  19. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029–35.

    Google Scholar 

  20. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.

    Google Scholar 

  21. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60.

    Article  CAS  PubMed  Google Scholar 

  22. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89–95.

    Article  PubMed  Google Scholar 

  23. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002;25:1919–27.

    Article  CAS  PubMed  Google Scholar 

  24. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen SP. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002;106:1453–9.

    Article  CAS  PubMed  Google Scholar 

  25. Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, Huttunen JK. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668–75.

    Article  CAS  PubMed  Google Scholar 

  26. Greenberg ER, Baron JA, Karagas MR, Stukel TA, Nierenberg DW, Stevens MM, Mandel JS, Haile RW. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA. 1996;275:699–703.

    Article  CAS  PubMed  Google Scholar 

  27. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.

    Article  CAS  PubMed  Google Scholar 

  28. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–5.

    Article  CAS  PubMed  Google Scholar 

  29. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.

    Article  CAS  PubMed  Google Scholar 

  30. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.

    Google Scholar 

  31. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40.

    Article  CAS  PubMed  Google Scholar 

  32. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–56.

    Article  CAS  PubMed  Google Scholar 

  33. Sheu S-S, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta (BBA) – Mol Basis Dis. 2006;1762:256–65.

    Article  CAS  Google Scholar 

  34. Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapies. Discov Med. 2011;11:106–14.

    PubMed  Google Scholar 

  35. Zhang ZW, Xu XC, Liu T, Yuan S. Mitochondrion-permeable antioxidants to treat ROS-burst-mediated acute diseases. Oxidative Med Cell Longev. 2016;2016:6859523.

    Google Scholar 

  36. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276:4588–96.

    Article  CAS  PubMed  Google Scholar 

  37. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280:21295–312.

    Article  CAS  PubMed  Google Scholar 

  38. McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31:15703–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, Kanthasamy A, Kalyanaraman B. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radic Biol Med. 2010;49:1674–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Chacko BK, Reily C, Srivastava A, Johnson MS, Ye Y, Ulasova E, Agarwal A, Zinn KR, Murphy MP, Kalyanaraman B, Darley-Usmar V. Prevention of diabetic nephropathy in Ins2(+/)(−)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J. 2010;432:9–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. von Montfort C, Matias N, Fernandez A, Fucho R, Conde de la Rosa L, Martinez-Chantar ML, Mato JM, Machida K, Tsukamoto H, Murphy MP, Mansouri A, Kaplowitz N, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis. J Hepatol. 2012;57:852–9.

    Article  CAS  Google Scholar 

  42. Chacko BK, Srivastava A, Johnson MS, Benavides GA, Chang MJ, Ye Y, Jhala N, Murphy MP, Kalyanaraman B, Darley-Usmar VM. Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology. 2011;54:153–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Pung YF, Rocic P, Murphy MP, Smith RA, Hafemeister J, Ohanyan V, Guarini G, Yin L, Chilian WM. Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler Thromb Vasc Biol. 2012;32:325–34.

    Article  CAS  PubMed  Google Scholar 

  44. Mercer JR, Yu E, Figg N, Cheng KK, Prime TA, Griffin JL, Masoodi M, Vidal-Puig A, Murphy MP, Bennett MR. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/−/ApoE−/− mice. Free Radic Biol Med. 2012;52:841–9.

    Article  CAS  PubMed  Google Scholar 

  45. Mitchell T, Rotaru D, Saba H, Smith RA, Murphy MP, MacMillan-Crow LA. The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys. J Pharmacol Exp Ther. 2011;336:682–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005;19:1088–95.

    Article  CAS  PubMed  Google Scholar 

  47. Dare AJ, Logan A, Prime TA, Rogatti S, Goddard M, Bolton EM, Bradley JA, Pettigrew GJ, Murphy MP, Saeb-Parsy K. The mitochondria-targeted anti-oxidant MitoQ decreases ischemia-reperfusion injury in a murine syngeneic heart transplant model. J Heart Lung Transplant. 2015;34:1471–80.

    Article  PubMed  PubMed Central  Google Scholar 

  48. McLachlan J, Beattie E, Murphy MP, Koh-Tan CH, Olson E, Beattie W, Dominiczak AF, Nicklin SA, Graham D. Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens. 2014;32:555–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322–8.

    Article  CAS  PubMed  Google Scholar 

  50. Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol. 2014;592:2549–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1095–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J. 2009;96:1388–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Vergeade A, Mulder P, Vendeville-Dehaudt C, Estour F, Fortin D, Ventura-Clapier R, Thuillez C, Monteil C. Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ. Free Radic Biol Med. 2010;49:748–56.

    Article  CAS  PubMed  Google Scholar 

  54. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25:1670–4.

    Article  PubMed  Google Scholar 

  55. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019–26.

    Article  CAS  PubMed  Google Scholar 

  56. Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999;263:709–16.

    Article  CAS  PubMed  Google Scholar 

  57. Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003;17:1972–4.

    CAS  PubMed  Google Scholar 

  58. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem. 2004;279:37575–87.

    Article  CAS  PubMed  Google Scholar 

  59. Siler-Marsiglio KI, Pan Q, Paiva M, Madorsky I, Khurana NC, Heaton MB. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res. 2005;1052:202–11.

    Article  CAS  PubMed  Google Scholar 

  60. Covey MV, Murphy MP, Hobbs CE, Smith RA, Oorschot DE. Effect of the mitochondrial antioxidant, Mito Vitamin E, on hypoxic-ischemic striatal injury in neonatal rats: a dose-response and stereological study. Exp Neurol. 2006;199:513–9.

    Article  CAS  PubMed  Google Scholar 

  61. Mao G, Kraus GA, Kim I, Spurlock ME, Bailey TB, Zhang Q, Beitz DC. A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice. J Nutr. 2010;140:1425–31.

    Article  CAS  PubMed  Google Scholar 

  62. Kurochkin IO, Etzkorn M, Buchwalter D, Leamy L, Sokolova IM. Top-down control analysis of the cadmium effects on molluscan mitochondria and the mechanisms of cadmium-induced mitochondrial dysfunction. Am J Physiol Regul Integr Comp Physiol. 2011;300:R21–31.

    Article  CAS  PubMed  Google Scholar 

  63. Babizhayev MA, Yegorov YE. Reactive oxygen species and the aging eye: specific role of metabolically active mitochondria in maintaining lens function and in the initiation of the oxidation-induced maturity onset cataract – a novel platform of mitochondria-targeted antioxidants with broad therapeutic potential for redox regulation and detoxification of oxidants in eye diseases. Am J Ther. 2016;23:e98–117.

    Article  PubMed  Google Scholar 

  64. Babizhayev MA. Generation of reactive oxygen species in the anterior eye segment. Synergistic codrugs of N-acetylcarnosine lubricant eye drops and mitochondria-targeted antioxidant act as a powerful therapeutic platform for the treatment of cataracts and primary open-angle glaucoma. BBA Clin. 2016;6:49–68.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Murphy MP, Echtay KS, Blaikie FH, Asin-Cayuela J, Cocheme HM, Green K, Buckingham JA, Taylor ER, Hurrell F, Hughes G, Miwa S, Cooper CE, Svistunenko DA, Smith RA, Brand MD. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. J Biol Chem. 2003;278:48534–45.

    Article  CAS  PubMed  Google Scholar 

  66. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer’s disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006;2006:31372.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Poeggeler B, Durand G, Polidori A, Pappolla MA, Vega-Naredo I, Coto-Montes A, Boker J, Hardeland R, Pucci B. Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH acting as a highly potent antioxidant agent. J Neurochem. 2005;95:962–73.

    Article  CAS  PubMed  Google Scholar 

  68. Filipovska A, Kelso GF, Brown SE, Beer SM, Smith RA, Murphy MP. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic. Insights into the interaction of ebselen with mitochondria. J Biol Chem. 2005;280:24113–26.

    Article  CAS  PubMed  Google Scholar 

  69. Stoyanovsky DA, Jiang J, Murphy MP, Epperly M, Zhang X, Li S, Greenberger J, Kagan V, Bayir H. Design and synthesis of a mitochondria-targeted mimic of glutathione peroxidase, MitoEbselen-2, as a radiation mitigator. ACS Med Chem Lett. 2014;5:1304–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV, Ivanova OY, Izyumov DS, Khailova LS, Klishin SS, Korshunova GA, Lyamzaev KG, Muntyan MS, Nepryakhina OK, Pashkovskaya AA, Pletjushkina OY, Pustovidko AV, Roginsky VA, Rokitskaya TI, Ruuge EK, Saprunova VB, Severina II, Simonyan RA, Skulachev IV, Skulachev MV, Sumbatyan NV, Sviryaeva IV, Tashlitsky VN, Vassiliev JM, Vyssokikh MY, Yaguzhinsky LS, Zamyatnin Jr AA, Skulachev VP. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochemistry (Mosc). 2008;73:1273–87.

    Article  CAS  Google Scholar 

  71. Bakeeva LE, Barskov IV, Egorov MV, Isaev NK, Kapelko VI, Kazachenko AV, Kirpatovsky VI, Kozlovsky SV, Lakomkin VL, Levina SB, Pisarenko OI, Plotnikov EY, Saprunova VB, Serebryakova LI, Skulachev MV, Stelmashook EV, Studneva IM, Tskitishvili OV, Vasilyeva AK, Victorov IV, Zorov DB, Skulachev VP. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc). 2008;73:1288–99.

    Article  CAS  Google Scholar 

  72. Manskikh VN, Gancharova OS, Nikiforova AI, Krasilshchikova MS, Shabalina IG, Egorov MV, Karger EM, Milanovsky GE, Galkin II, Skulachev VP, Zinovkin RA. Age-associated murine cardiac lesions are attenuated by the mitochondria-targeted antioxidant SkQ1. Histol Histopathol. 2015;30:353–60.

    CAS  PubMed  Google Scholar 

  73. Skulachev MV, Antonenko YN, Anisimov VN, Chernyak BV, Cherepanov DA, Chistyakov VA, Egorov MV, Kolosova NG, Korshunova GA, Lyamzaev KG, Plotnikov EY, Roginsky VA, Savchenko AY, Severina II, Severin FF, Shkurat TP, Tashlitsky VN, Shidlovsky KM, Vyssokikh MY, Zamyatnin Jr AA, Zorov DB, Skulachev VP. Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies. Curr Drug Targets. 2011;12:800–26.

    Article  CAS  PubMed  Google Scholar 

  74. Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33:96–115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682–90.

    Article  CAS  PubMed  Google Scholar 

  76. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 2006;8:E277–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol. 2005;70:1796–806.

    Article  CAS  PubMed  Google Scholar 

  78. Thomas DA, Stauffer C, Zhao K, Yang H, Sharma VK, Szeto HH, Suthanthiran M. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol. 2007;18:213–22.

    Article  CAS  PubMed  Google Scholar 

  79. Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, Zhao Z, Ganger M, Tow CY, Seshan SV. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22:1041–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Liu S, Soong Y, Seshan SV, Szeto HH. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis. Am J Physiol Renal Physiol. 2014;306:F970–80.

    Article  CAS  PubMed  Google Scholar 

  81. Mizuguchi Y, Chen J, Seshan SV, Poppas DP, Szeto HH, Felsen D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2008;295:F1545–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Hou Y, Li S, Wu M, Wei J, Ren Y, Du C, Wu H, Han C, Duan H, Shi Y. Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. Am J Physiol Renal Physiol. 2016;310:F547–59.

    Article  CAS  PubMed  Google Scholar 

  83. Wu J, Zhang M, Li H, Sun X, Hao S, Ji M, Yang J, Li K. BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced cognitive deficits in aging mice. Behav Brain Res. 2016;305:115–21.

    Article  CAS  PubMed  Google Scholar 

  84. Wu J, Zhang M, Hao S, Jia M, Ji M, Qiu L, Sun X, Yang J, Li K. Mitochondria-targeted peptide reverses mitochondrial dysfunction and cognitive deficits in sepsis-associated encephalopathy. Mol Neurobiol. 2015;52:783–91.

    Article  CAS  PubMed  Google Scholar 

  85. Siegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, Kavanagh TJ, Szeto HH, Rabinovitch PS, Marcinek DJ. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Righi V, Constantinou C, Mintzopoulos D, Khan N, Mupparaju SP, Rahme LG, Swartz HM, Szeto HH, Tompkins RG, Tzika AA. Mitochondria-targeted antioxidant promotes recovery of skeletal muscle mitochondrial function after burn trauma assessed by in vivo 31P nuclear magnetic resonance and electron paramagnetic resonance spectroscopy. FASEB J. 2013;27:2521–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Lee HY, Kaneki M, Andreas J, Tompkins RG, Martyn JA. Novel mitochondria-targeted antioxidant peptide ameliorates burn-induced apoptosis and endoplasmic reticulum stress in the skeletal muscle of mice. Shock. 2011;36:580–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Wu D, Soong Y, Zhao GM, Szeto HH. A highly potent peptide analgesic that protects against ischemia-reperfusion-induced myocardial stunning. Am J Physiol Heart Circ Physiol. 2002;283:H783–91.

    Article  CAS  PubMed  Google Scholar 

  89. Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK. Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 2007;18:215–20.

    Article  PubMed  Google Scholar 

  90. Dai DF, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF, Rabinovitch PS. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011;58:73–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509–14. e7

    Article  CAS  PubMed  Google Scholar 

  92. Kikuchi K, Tancharoen S, Takeshige N, Yoshitomi M, Morioka M, Murai Y, Tanaka E. The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 2013;14:13909–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Ji L, Liu Y, Zhang Y, Chang W, Gong J, Wei S, Li X, Qin L. The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative stress in type 1 diabetic rats and in high-glucose-induced injured H9c2 cardiomyoblasts. Can J Physiol Pharmacol. 2016;94:996–1006.

    Article  CAS  PubMed  Google Scholar 

  94. Zhang GW, Gu TX, Sun XJ, Wang C, Qi X, Wang XB, Li-Ling J. Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. J Thorac Cardiovasc Surg. 2016;152:570–82.

    Article  CAS  PubMed  Google Scholar 

  95. Hassan MQ, Akhtar MS, Akhtar M, Ali J, Haque SE, Najmi AK. Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. Ther Adv Cardiovasc Dis. 2016;10:214–23.

    Article  PubMed  Google Scholar 

  96. Rajesh KG, Sasaguri S, Suzuki R, Maeda H. Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol. 2003;285:H2171–8.

    Article  CAS  PubMed  Google Scholar 

  97. Tsujita K, Shimomura H, Kawano H, Hokamaki J, Fukuda M, Yamashita T, Hida S, Nakamura Y, Nagayoshi Y, Sakamoto T, Yoshimura M, Arai H, Ogawa H. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:481–4.

    Article  CAS  PubMed  Google Scholar 

  98. Gueven N, Woolley K, Smith J. Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10. Redox Biol. 2015;4:289–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun. 1984;125:1046–52.

    Article  CAS  PubMed  Google Scholar 

  100. Sugiyama Y, Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett. 1985;184:48–51.

    Article  CAS  PubMed  Google Scholar 

  101. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology. 2003;61:1498–502.

    Article  CAS  PubMed  Google Scholar 

  102. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, Rummey C, Meier T, Lynch DR. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J. 2011;161:639–45. e1

    Article  CAS  PubMed  Google Scholar 

  103. Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M. Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. 2016;8:CD007791.

    Google Scholar 

  104. Buyse GM, Voit T, Schara U, Straathof CS, D’Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015;385:1748–57.

    Article  CAS  PubMed  Google Scholar 

  105. McDonald CM, Meier T, Voit T, Schara U, Straathof CS, D’Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, Rummey C, Leinonen M, Spagnolo P, Buyse GM. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:473–80.

    Article  PubMed  Google Scholar 

  106. Gueven N. Idebenone for Leber’s hereditary optic neuropathy. Drugs Today (Barc). 2016;52:173–81.

    Article  CAS  Google Scholar 

  107. Rustin P, Rotig A, Munnich A, Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich’s ataxia. Free Radic Res. 2002;36:467–9.

    Article  CAS  PubMed  Google Scholar 

  108. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676–9.

    Article  CAS  PubMed  Google Scholar 

  109. Velasco-Sanchez D, Aracil A, Montero R, Mas A, Jimenez L, O’Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M. Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia. Cerebellum. 2011;10:1–8.

    Article  CAS  PubMed  Google Scholar 

  110. Arpa J, Sanz-Gallego I, Rodriguez-de-Rivera FJ, Dominguez-Melcon FJ, Prefasi D, Oliva-Navarro J, Moreno-Yanguela M. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich’s ataxia – open-label trial. Acta Neurol Scand. 2014;129:32–40.

    Article  CAS  PubMed  Google Scholar 

  111. Kim HJ, Koo SY, Ahn BH, Park O, Park DH, Seo DO, Won JH, Yim HJ, Kwak HS, Park HS, Chung CW, Oh YL, Kim SH. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO(-) scavenger. Arch Pharm Res. 2010;33:1813–23.

    Article  CAS  PubMed  Google Scholar 

  112. Thu VT, Kim HK, Long le T, Nyamaa B, Song IS, Thuy TT, Huy NQ, Marquez J, Kim SH, Kim N, Ko KS, Rhee BD, Han J. NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1alpha expression levels during hypoxia/reoxygenation injury. Korean J Physiol Pharmacol. 2016;20:201–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Thu VT, Kim HK, Long le T, Lee SR, Hanh TM, Ko TH, Heo HJ, Kim N, Kim SH, Ko KS, Rhee BD, Han J. NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter. Cardiovasc Res. 2012;94:342–50.

    Article  CAS  PubMed  Google Scholar 

  114. Choi JM, Park KM, Kim SH, Hwang DW, Chon SH, Lee JH, Lee SY, Lee YJ. Effect of necrosis modulator necrox-7 on hepatic ischemia-reperfusion injury in beagle dogs. Transplant Proc. 2010;42:3414–21.

    Article  CAS  PubMed  Google Scholar 

  115. Lee DW, Lee TK, Cho IS, Park HE, Jin S, Cho HJ, Kim SH, Oh S, Kim HS. Creation of myocardial fibrosis by transplantation of fibroblasts primed with survival factors. Am J Physiol Heart Circ Physiol. 2011;301:H1004–14.

    Article  CAS  PubMed  Google Scholar 

  116. Park JH, Seo KS, Tadi S, Ahn BH, Lee JU, Heo JY, Han J, Song MS, Kim SH, Yim YH, Choi HS, Shong M, Kweon G. An indole derivative protects against acetaminophen-induced liver injury by directly binding to N-acetyl-p-benzoquinone imine in mice. Antioxid Redox Signal. 2013;18:1713–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Kim SR, Kim DI, Kim SH, Lee H, Lee KS, Cho SH, Lee YC. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis. 2014;5:e1498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Jin SA, Kim SK, Seo HJ, Jeong JY, Ahn KT, Kim JH, Choi DE, Park JH, Lee JH, Choi SW, Seong IW, Kim SH, Suh KS, Jeong JO. Beneficial effects of necrosis modulator, indole derivative NecroX-7, on renal ischemia-reperfusion injury in rats. Transplant Proc. 2016;48:199–204.

    Article  CAS  PubMed  Google Scholar 

  119. Biswas SK. NecroX-7 may appear as a new molecule to stabilize atherosclerotic plaques. Atherosclerosis. 2016;252:190–1.

    Google Scholar 

  120. Grootaert MO, Schrijvers DM, Van Spaendonk H, Breynaert A, Hermans N, Van Hoof VO, Takahashi N, Vandenabeele P, Kim SH, De Meyer GR, Martinet W. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis. 2016;252:166–74.

    Article  CAS  PubMed  Google Scholar 

  121. Fassett RG, Coombes JS. Astaxanthin: a potential therapeutic agent in cardiovascular disease. Mar Drugs. 2011;9:447–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Kuroki T, Ikeda S, Okada T, Maoka T, Kitamura A, Sugimoto M, Kume S. Astaxanthin ameliorates heat stress-induced impairment of blastocyst development in vitro: – astaxanthin colocalization with and action on mitochondria. J Assist Reprod Genet. 2013;30:623–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Manabe E, Handa O, Naito Y, Mizushima K, Akagiri S, Adachi S, Takagi T, Kokura S, Maoka T, Yoshikawa T. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem. 2008;103:1925–37.

    Article  CAS  PubMed  Google Scholar 

  124. Liu X, Osawa T. Astaxanthin protects neuronal cells against oxidative damage and is a potent candidate for brain food. Forum Nutr. 2009;61:129–35.

    Article  CAS  PubMed  Google Scholar 

  125. Liu X, Shibata T, Hisaka S, Osawa T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res. 2009;1254:18–27.

    Article  CAS  PubMed  Google Scholar 

  126. Kurashige M, Okimasu E, Inoue M, Utsumi K. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR. 1990;22:27–38.

    CAS  PubMed  Google Scholar 

  127. Lee DH, Kim CS, Lee YJ. Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol. 2011;49:271–80.

    Article  CAS  PubMed  Google Scholar 

  128. Gaki GS, Papavassiliou AG. Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson’s disease. Neruomol Med. 2014;16:217–30.

    Article  CAS  Google Scholar 

  129. Curek GD, Cort A, Yucel G, Demir N, Ozturk S, Elpek GO, Savas B, Aslan M. Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion. Toxicology. 2010;267:147–53.

    Article  CAS  PubMed  Google Scholar 

  130. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Res. 2010;30:2721–5.

    CAS  PubMed  Google Scholar 

  131. Gross GJ, Lockwood SF. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci. 2004;75:215–24.

    Article  CAS  PubMed  Google Scholar 

  132. Gross GJ, Hazen SL, Lockwood SF. Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. Mol Cell Biochem. 2006;283:23–30.

    Article  CAS  PubMed  Google Scholar 

  133. Hussein G, Nakamura M, Zhao Q, Iguchi T, Goto H, Sankawa U, Watanabe H. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005;28:47–52.

    Article  CAS  PubMed  Google Scholar 

  134. Gross GJ, Lockwood SF. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem. 2005;272:221–7.

    Article  CAS  PubMed  Google Scholar 

  135. Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, Gaudio C, Rosano G. Usefulness of nutraceuticals (armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol. 2015;116:1798–801.

    Article  CAS  PubMed  Google Scholar 

  136. Maki KC, Geohas JG, Dicklin MR, Huebner M, Udani JK. Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols. Prostaglandins Leukot Essent Fat Acids. 2015;99:41–6.

    Article  CAS  Google Scholar 

  137. Coombes JS, Sharman JE, Fassett RG. Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). Am J Clin Nutr. 2016;103:283–9.

    Article  CAS  PubMed  Google Scholar 

  138. Suzuki T, Yamaguchi H, Kikusato M, Matsuhashi T, Matsuo A, Sato T, Oba Y, Watanabe S, Minaki D, Saigusa D, Shimbo H, Mori N, Mishima E, Shima H, Akiyama Y, Takeuchi Y, Yuri A, Kikuchi K, Toyohara T, Suzuki C, Kohzuki M, Anzai J, Mano N, Kure S, Yanagisawa T, Tomioka Y, Toyomizu M, Ito S, Osaka H, Hayashi K, Abe T. Mitochonic acid 5 (MA-5), a derivative of the plant hormone indole-3-acetic acid, improves survival of fibroblasts from patients with mitochondrial diseases. Tohoku J Exp Med. 2015;236:225–32.

    Article  CAS  PubMed  Google Scholar 

  139. Suzuki T, Yamaguchi H, Kikusato M, Hashizume O, Nagatoishi S, Matsuo A, Sato T, Kudo T, Matsuhashi T, Murayama K, Ohba Y, Watanabe S, Kanno S, Minaki D, Saigusa D, Shinbo H, Mori N, Yuri A, Yokoro M, Mishima E, Shima H, Akiyama Y, Takeuchi Y, Kikuchi K, Toyohara T, Suzuki C, Ichimura T, Anzai J, Kohzuki M, Mano N, Kure S, Yanagisawa T, Tomioka Y, Toyomizu M, Tsumoto K, Nakada K, Bonventre JV, Ito S, Osaka H, Hayashi K, Abe T. Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte mamage. J Am Soc Nephrol. 2016;27:1925–32.

    Article  PubMed  Google Scholar 

  140. Cerrato CP, Pirisinu M, Vlachos EN, Langel U. Novel cell-penetrating peptide targeting mitochondria. FASEB J. 2015;29:4589–99.

    Article  CAS  PubMed  Google Scholar 

  141. Bi W, Bi Y, Gao X, Yan X, Zhang Y, Xue P, Bammert CE, Legalley TD, Michael Gibson K, Bi L, Wang JX. Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules. Bioorg Med Chem Lett. 2016;26:2005–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Priority Research Centers Program through the National Research Foundation of Korea (NRF), Funded by the Ministry of Education, Science and Technology (2010-0020224, 2015R1A2A1A13001900 and 2015R1D1A1A01057937), Republic Korea.

Author information

Authors and Affiliations

  1. National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 plus Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Bokji-ro 75, Busanjin-gu, Busan, 47392, Korea

    Hyoung Kyu Kim & Jin Han

  2. Department of Integrated Biomedical Science, College of Medicine, Inje University, Busan, Korea

    Hyoung Kyu Kim

Authors
  1. Hyoung Kyu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin Han .

Editor information

Editors and Affiliations

  1. Dept. of Biomedical Advanced Sciences, Federico II University, Naples, Italy

    Gaetano Santulli

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kim, H.K., Han, J. (2017). Mitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders. In: Santulli, G. (eds) Mitochondrial Dynamics in Cardiovascular Medicine. Advances in Experimental Medicine and Biology, vol 982. Springer, Cham. https://doi.org/10.1007/978-3-319-55330-6_32

Download citation

Publish with us

Policies and ethics

Search

Navigation